NAGE
NAGE
NASDAQ · Life Sciences Tools & Services

Niagen Bioscience Inc

$2.01
+0.00 (+0.00%)
As of Nov 17, 8:31 PM ET ·
Financial Highlights (FY 2026)
Revenue
117.73M
Net Income
15.81M
Gross Margin
64.3%
Profit Margin
13.4%
Rev Growth
+21.6%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 64.3% 64.3% 42.4% 42.4%
Operating Margin 12.6% 11.3% 16.1% 15.1%
Profit Margin 13.4% 12.8% 12.4% 10.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 117.73M 96.85M 119.93M 113.70M
Gross Profit 75.68M 62.25M 50.83M 48.19M
Operating Income 14.81M 10.97M 19.31M 17.15M
Net Income 15.81M 11.71M 14.89M 12.09M
Gross Margin 64.3% 64.3% 42.4% 42.4%
Operating Margin 12.6% 11.3% 16.1% 15.1%
Profit Margin 13.4% 12.8% 12.4% 10.6%
Rev Growth +21.6% +21.6% +11.4% +12.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 133.61M 160.13M
Total Equity — — 171.80M 169.78M
D/E Ratio — — 0.78 0.94
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 15.36M 12.01M 27.61M 22.05M
Free Cash Flow — — 17.96M 17.42M